“CMO of Sterile Injectable Drugs market is expected to surpass US$55,000.0 million by 2030” says new Visiongain report

04 May 2020
Pharma

Visiongain has launched a new pharma report Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030: Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors, Others), Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), Molecule (Small Molecule and Large Molecule), Container (Bottles, Ampoules, Vials, Bags, Pre-filled Syringes, Others) Plus Company Profiling of Major Players.

The global contract manufacturing of sterile injectable drugs market was valued at US$13,887.5 million in 2019 and is expected to surpass US$55,000.0 million by 2030 while growing at a CAGR of over 13% over 2020-2030. Increasing prevalence of chronic diseases, fostering demand for biologics in the coming years along with patent cliff are key factors driving the growth of the global contract manufacturing of sterile injectable drugs market.

The scope of the report is segmented into product, molecule, container, and region. In the molecule segment, a small molecule held the largest market share in 2019 and will continue to dominate throughout the forecast period. This is attributed to the increasing number of product approvals by healthcare authorities globally.

Based on the product, the monoclonal antibodies segment accounted for significant revenue share in 2019 and is expected to register the lucrative growth over the forecast period. The monoclonal antibodies were valued at over US$5,000.0 million in 2019 which is further projected to exceed US$21,000.0 million by 2030 while growing at a CAGR of more than 12% over the forecast period.

Based on the application, the cardiovascular diseases segment held the largest revenue share in 2018. Furthermore, the cancer segment is likely to exhibit rapid growth over the forecast period. The segment is anticipated to witness a CAGR of 14.2% over the forecast period.

Europe currently holds the largest share in 2019 for contract manufacturing of sterile injectable market owing to the presence of a significant number of contract manufacturers for injectable in the region. Moreover, growing investments by contract manufacturers on using advance-manufacturing processes has also accounted for the largest share in the global market. The European market for contract manufacturing of sterile injectable was valued at over US$4,000.0 million in 2019 which is further projected to witness a CAGR of 13.2% by 2030.

Furthermore, Asia Pacific is going to record growth at a faster pace because of developing healthcare infrastructure. The market was valued at over US$2,000.0 million in 2019 which is projected to witness the fastest growth rate of 14.7% to surpass US$13,000.0 million by 2030.

The prominent players operating in global contract manufacturing of injectable drugs market include Boehringer Ingelheim, Famar Health Care Services, Siegfried Holding AG, Jubilant Life Sciences, Ltd., Grifols SA, Pfizer CentreOne, Catalent Inc, Aenova Group, Baxter Biopharma Solutions, Recipharm AB, Lonza, Patheon Inc., Almac Group, Evonik Industries AG, and Consort Medical Plc among other prominent players operating across the globe.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020

Read

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever